Physician profile
Amy Knickerbocker
NPI 1194209031
$2,142.22
in general payments reported to CMS, 2019-2025
23 companies · $710 in 2025
The $710 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $318 · 2023: $113 · 2024: $338 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.13 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $589.77 | 2021-2025 | Mounjaro, Trulicity, Humulin |
| Novo Nordisk INC | $359.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $311.88 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.95 | 2024-2025 | Jardiance |
| Amgen INC. | $119.33 | 2021-2025 | Tepezza |
| Ibsa Pharma INC. | $107.03 | 2024-2025 | Licart, Tirosint, Flector |
| Abbvie INC. | $93.12 | 2022-2025 | |
| Medtronic, INC. | $55.13 | 2024-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $45.68 | 2025 | |
| Abbott Laboratories | $35.43 | 2024-2025 | Freestyle Libre 3 |
| Acella Pharmaceuticals, LLC | $29.14 | 2024 | NP Thyroid 60 |
| Ascensia Diabetes Care US INC. | $28.96 | 2024 | |
| Kyowa Kirin, INC. | $26.55 | 2024 | Crysvita |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Mannkind Corporation | $24.97 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.84 | 2024 | Gvoke Hypopen |
| Corcept Therapeutics | $23.77 | 2024 | Korlym |
| Tandem Diabetes Care, INC. | $23.43 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $22.76 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $20.13 | 2025 | |
| Antares Pharma, INC. | $19.24 | 2025 | Xyosted |
| Amphastar Pharmaceuticals, INC. | $16.05 | 2025 | |
| Dexcom, INC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Knickerbocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.